A new diethylcarbamazine formulation (NANO-DEC) as a therapeutic tool for hepatic fibrosis

Rodrigues, Gabriel Barros; Oliveira, Elquio Eleamen; Mendonça, Francisco Jaime Bezerra; Santos, Laise Aline Martins dos; Oliveira, W.; França, Maria Eduarda Rocha de; Lós, Deniele Bezerra; Gabínio, Brennda Martins; Peixoto, Christina Alves

doi:10.1016/j.intimp.2018.09.010

Cited by 3 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, the nanoparticles have demonstrated the ability to enhance the therapeutic activity of DEC using a dose of 12.5 mg/ kg for 6 days, which is less than that reported previously (50 mg/kg) (Rocha et al, 2012;Silva et al, 2014). The enhanced activity may have been a consequence of the improved residence time of the drug-loaded nanoparticles (Rodrigues et al, 2017;Rodrigues et al, 2018).…”

Section: Development Of Diethylcarbamazine-loaded Poly(caprolactone) ...mentioning

confidence: 78%

Development of diethylcarbamazine-loaded poly(caprolactone) nanoparticles for anti-inflammatory purpose: Preparation and characterization

Marcelino

Gabínio

Lima

et al. 2022

Braz. J. Pharm. Sci.

Self Cite

View full text Add to dashboard Cite

Diethylcarbamazine-loaded nanoparticles were previously evaluated for their anti-inflammatory activity. However, little is known regarding their physicochemical properties. Thus, the purpose of this study was to physiochemically characterize diethylcarbamazine-loaded poly(caprolactone) nanoparticles and evaluate their in vitro cytotoxicity. All formulations were prepared using the double-emulsion method. The average particle size was in the ranged between 298 and 364 nm and the polydispersity indexes were below 0.3. The zeta potential values were marginally negative, which may be related to drug loading, as higher loading led to an increase in the modulus of the zeta potential values. Fourier transform infrared spectroscopy (FT-IR) and X-ray powder diffraction (XRD) analysis did not reveal any chemical interactions between the chemicals used and the absence of drug in crystalline form on the nanoparticle surfaces. The in vitro drug release study revealed a concentration-dependent release from the nanoparticles into the medium. The in vitro cytotoxicity assay demonstrated the biocompatibility of the blank and loaded nanoparticles. Hence, all formulations presented good physicochemical and safety properties, corroborating the in vivo anti-inflammatory activity, previously reported by our group.

show abstract

Section: Development Of Diethylcarbamazine-loaded Poly(caprolactone) ...mentioning

confidence: 78%

Development of diethylcarbamazine-loaded poly(caprolactone) nanoparticles for anti-inflammatory purpose: Preparation and characterization

Marcelino

Gabínio

Lima

et al. 2022

Braz. J. Pharm. Sci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…DEC is a safe and non-expensive drug with side effects mainly related to parasitic infection. The recently reported activities of DEC include immunomodulatory [2] , [3] , anti-inflammatory [4] , and antifibrotic activities [5] , [6] ; hence, the potential of DEC is beyond its original use as an antifilarial agent. DEC protects against acute lung injury [7] and shows an antifibrotic effect in experimental liver fibrosis [5] , [6] , a condition that shares common pathways with lung fibrosis [8] .…”

mentioning

confidence: 99%

“…The recently reported activities of DEC include immunomodulatory [2] , [3] , anti-inflammatory [4] , and antifibrotic activities [5] , [6] ; hence, the potential of DEC is beyond its original use as an antifilarial agent. DEC protects against acute lung injury [7] and shows an antifibrotic effect in experimental liver fibrosis [5] , [6] , a condition that shares common pathways with lung fibrosis [8] . We believe that the antifibrotic activity suggests a significant potential of DEC for treating COVID-19-related lung damage.…”

mentioning

confidence: 99%

“…DEC reduces the production of fibrotic factors and collagen [9] , [10] , [11] and the expression of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) [11] , thus inhibiting the production of the profibrotic cytokines, interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α. IL-1β and IL-6 influence the inflammatory and fibrotic response by inducing the activation and accumulation of neutrophils and lymphocytes to the injury site and promoting the activation of fibroblasts and collagen synthesis [12] . DEC reduces the expression of transforming growth factor (TGF)-β [5] , [6] , a potent profibrotic cytokine, that induces the production and deposition of extracellular matrix (ECM) [13] .…”

mentioning

confidence: 99%

“…Additionally, DEC decreases tissue inhibitor of metalloproteinase (TIMP)-1 expression, further increasing metalloproteinase (MMP)-2 expression, ECM accumulation, and fibrosis [5] , [6] . It would be clinically relevant to determine whether DEC may reduce the tissue damage leading to fibrosis or act upon already established lesions in patients in the acute stage or those recovering from post-COVID-19 fibrosis.…”

mentioning

confidence: 99%

See 2 more Smart Citations